Fjarde AP Fonden Fourth Swedish National Pension Fund decreased its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 4.1% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 67,360 shares of the pharmaceutical company’s stock after selling 2,902 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Vertex Pharmaceuticals were worth $12,983,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of VRTX. Fiera Capital Corp raised its stake in shares of Vertex Pharmaceuticals by 12.7% in the second quarter. Fiera Capital Corp now owns 2,591 shares of the pharmaceutical company’s stock worth $440,000 after buying an additional 292 shares during the period. Twin Capital Management Inc. raised its stake in shares of Vertex Pharmaceuticals by 0.7% in the second quarter. Twin Capital Management Inc. now owns 43,770 shares of the pharmaceutical company’s stock worth $7,439,000 after buying an additional 300 shares during the period. Impax Asset Management LLC raised its stake in shares of Vertex Pharmaceuticals by 11.2% in the second quarter. Impax Asset Management LLC now owns 2,998 shares of the pharmaceutical company’s stock worth $510,000 after buying an additional 302 shares during the period. Brown Advisory Inc. raised its stake in shares of Vertex Pharmaceuticals by 5.0% in the second quarter. Brown Advisory Inc. now owns 6,327 shares of the pharmaceutical company’s stock worth $1,075,000 after buying an additional 304 shares during the period. Finally, Sumitomo Mitsui Asset Management Company LTD raised its stake in shares of Vertex Pharmaceuticals by 1.8% in the second quarter. Sumitomo Mitsui Asset Management Company LTD now owns 17,914 shares of the pharmaceutical company’s stock worth $3,044,000 after buying an additional 325 shares during the period. 94.95% of the stock is currently owned by institutional investors.

VRTX opened at $161.07 on Tuesday. The firm has a market capitalization of $42.20 billion, a PE ratio of 73.71, a P/E/G ratio of 1.64 and a beta of 1.61. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.71 and a quick ratio of 3.59. Vertex Pharmaceuticals Incorporated has a 12 month low of $136.50 and a 12 month high of $194.92.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Wednesday, October 24th. The pharmaceutical company reported $1.09 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.02 by $0.07. The firm had revenue of $784.54 million for the quarter, compared to the consensus estimate of $782.95 million. Vertex Pharmaceuticals had a return on equity of 22.92% and a net margin of 22.87%. During the same period in the previous year, the business earned $0.53 EPS. Research analysts expect that Vertex Pharmaceuticals Incorporated will post 2.55 earnings per share for the current year.

Several analysts recently issued reports on VRTX shares. BMO Capital Markets lifted their target price on Vertex Pharmaceuticals to $204.00 and gave the company an “outperform” rating in a research note on Thursday, July 26th. Piper Jaffray Companies lifted their target price on Vertex Pharmaceuticals to $230.00 and gave the company an “overweight” rating in a research note on Thursday, July 26th. Oppenheimer lifted their target price on Vertex Pharmaceuticals from $180.00 to $200.00 and gave the company an “outperform” rating in a research note on Thursday, July 26th. Morgan Stanley lifted their target price on Vertex Pharmaceuticals from $207.00 to $211.00 and gave the company an “overweight” rating in a research note on Thursday, July 26th. Finally, UBS Group lifted their target price on Vertex Pharmaceuticals from $183.00 to $188.00 and gave the company a “neutral” rating in a research note on Thursday, July 26th. Three equities research analysts have rated the stock with a hold rating and twenty-two have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $201.14.

In other Vertex Pharmaceuticals news, CFO Thomas Graney sold 1,076 shares of the business’s stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $193.24, for a total transaction of $207,926.24. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CMO Reshma Kewalramani sold 2,305 shares of the business’s stock in a transaction dated Monday, October 8th. The shares were sold at an average price of $186.95, for a total value of $430,919.75. Following the sale, the chief marketing officer now owns 1,909 shares in the company, valued at approximately $356,887.55. The disclosure for this sale can be found here. In the last quarter, insiders have sold 29,662 shares of company stock worth $5,500,575. Company insiders own 0.75% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Fjarde AP Fonden Fourth Swedish National Pension Fund Sells 2,902 Shares of Vertex Pharmaceuticals Incorporated (VRTX)” was posted by Daily Political and is owned by of Daily Political. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://www.dailypolitical.com/2018/11/20/fjarde-ap-fonden-fourth-swedish-national-pension-fund-sells-2902-shares-of-vertex-pharmaceuticals-incorporated-vrtx.html.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for the treatment of patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor.

Recommended Story: Compound Annual Growth Rate (CAGR)

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.